Phase 2 study of oregovomab in combination with a TLR3 agonist, Hiltonol®, in the recurrent ovarian cancer
Latest Information Update: 12 Dec 2016
At a glance
- Drugs Oregovomab (Primary) ; Poly ICLC
- Indications Ovarian cancer
- Focus Therapeutic Use
- 12 Dec 2016 New trial record